EXPE vs STRO · P/E 20, rev $13.69B vs rev $62.0M
Expedia Group Inc. (EXPE) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Expedia Group Inc. (EXPE) is a travel services company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported EXPE revenue for 2024-12-31 was $13.69B. Net income was $1.22B. Revenue was up 6.6% from 2023-12-31 to 2024-12-31. EXPE currently screens at market cap $21.71B and trailing P/E 20.4.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
EXPE currently screens at market cap $21.71B and trailing P/E 20.4. STRO currently screens at market cap $470.8M.
Not investment advice. Open the EXPE and STRO stock pages for the full models.
Not investment advice.